Journal
JOURNAL OF HEPATOLOGY
Volume 59, Issue 2, Pages 375-382Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2013.03.030
Keywords
Hepatitis C virus; NS5A inhibitor; Daclatasvir; Resistance
Categories
Funding
- Achillion Pharmaceuticals
Ask authors/readers for more resources
Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation. Significant research has been devoted to developing direct-acting antiviral agents that inhibit key viral functions. In particular, several novel drug candidates that inhibit the viral non-structural protein 5A (NS5A) have been demonstrated to possess high potency, pan-genotypic activity, and a high barrier to resistance. Clinical trials using combination therapies containing NS5A inhibitors have reported results that promise high cure rates and raise the possibility of developing interferon-free, all-oral regimens. (C) 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available